SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma

Modern Pathology

Volumn 26, Issue 3, 2013, Pages 393-403

  Papp, Gerg ^a   Changchien, Yi Che ^a   Péterfia, Bálint ^a   Pecsenka, Loránd ^b   Krausz, Thomas ^c   Stricker, Thomas P ^d   Khoor, Andras ^e   Donner, Ludvik ^f,g   Sápi, Zoltán ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e MAYO CLINIC   (United States)

^f SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^g Sherwood and Brindley Foundation   (United States)

Author keywords

epithelioid sarcoma; histone methylation; laser capture microdissection; methylation specific PCR; promoter hypermethylation; SMARCB1

Indexed keywords

GENOMIC DNA; HISTONE; MESSENGER RNA; NUCLEAR PROTEIN; SMARCB1 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EPITHELIOID SARCOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; HISTONE METHYLATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

EID: 84875216002     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.190     Document Type: Article

References (29)

1. Kalpana GV, Marmon S, Wang W, et al. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 1994;266: 2002-2006.
2. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009;28:1653-1668.
3. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203-206.
4. Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol 2011;35:e47-e63.
5. Enzinger FM. Epitheloid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer 1970;26: 1029-1041.
6. Chase DR, Enzinger FM. Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol 1985;9:241-263.
7. Modena P, Lualdi E, Facchinetti F, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 2005;65:4012-4019.
8. Chbani L, Guillou L, Terrier P, et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol 2009;131:222-227.
9. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 2009;33:542-550.
10. Kohashi K, Izumi T, Oda Y, et al. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 2009;40:349-355.
11. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
12. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707-717.
13. Cao R,Wang L,Wang H, et al. Role of histone H3 lysine methylation in Polycomb-group silencing. Science 2002;298:1039-1043.
14. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629.
15. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606-11611.
16. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008;647:21-29.
17. Ciarapica R, Miele L, Giordano A, et al. Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. BMC Med 2011;9:63.
18. Pacheco M, Nielsen TO. Histone deacetylase 1 and in mesenchymal tumors. Mod Pathol 2012;25: 222-230.
19. Kohashi K, Oda Y, Yamamoto H, et al. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR. J Cancer Res Clin Oncol 2007;133:817-824.
20. Venneti S, Le P, Martinez D, et al. Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins. Am J Surg Pathol 2011;35:1463-1472.
21. Handgretinger R, Kimmig A, Koscielnak E, et al. Establishment and characterization of a cell line (Wa-2) derived from an extrarenal rhabdoid tumor. Cancer Res 1990;50:2177-2182.
22. Zhang F, Tan L, Wainwright LM, et al. No evidence for hypermethylation of the hSNF5/INI1 promoter in pediatric rhabdoid tumors. Genes Chromosomes Cancer 2002;34:398-405.
23. Skiriute D, Vaitkiene P, Saferis V, et al. MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastom. BMC Cancer 2012;12:218.
24. Wang D, Chen Q, Zhang C, et al. DNA hypomethylation of the COX-2 gene promoter is associated with upregulation of its mRNA expression in eutopic endometrium of endometriosis. Eur J Med Res 2012;17:12.
25. Wang C, Liu Z, Woo CW, et al. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res 2012;72:315-324.
26. Burdach S, Plehm S, Unland R, et al. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle 2009;8:1991-1996.
27. Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008;27:7274-7284.
28. Yamaga K, Osaki M, Kidani K, et al. High expression of enhancer of zeste homologue 2 indicates poor prognosis in patients with soft tissue sarcomas. Mol Med Report 2008;1:633-639.
29. Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS 2007;115:1090-1106.